Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (ALLK)
NASDAQ:ALLK
Allakos (ALLK) Stock Price & Analysis
214 Followers
ALLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $5.64
Previous Close$1.05
Volume155.73K
Average Volume (3M)785.94K
Market Cap
$90.46M
Enterprise Value-$40.31M
Total Cash (Recent Filing)$170.79M
Total Debt (Recent Filing)$38.22M
Price to Earnings (P/E)-0.5
Beta1.04
Next Earnings
May 07, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding87,873,995
10 Day Avg. Volume359,352
30 Day Avg. Volume785,943
Standard Deviation0.31
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$4.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Allakos News
PremiumCompany Announcements
Allakos Inc. Announces Board of Directors Reshuffle
PremiumCompany Announcements
Allakos Inc Reveals Breakthrough AK006 Data in Allergy JournalBulls Say, Bears Say
Bulls Say
Clinical Trial MilestonesTopline data from the Phase 1 study of IV AK006 in chronic spontaneous urticaria patients is expected, which could potentially result in a large upside move for the company.
Drug Development ProgressAllakos has initiated a placebo-controlled Phase 1 trial of subcutaneous AK006 in healthy volunteers, with topline results anticipated.
Financial StabilityThe company ended the year with $171M in cash, which management expects provides runway into mid-2026.
Bears Say
Clinical TrialsA series of Ph. III trials for lirentelimab missed on the co-primary symptom score endpoints.
Drug DevelopmentFollowing recent disappointing Phase 2 results for lirentelimab in atopic dermatitis and chronic spontaneous urticaria, ALLK discontinued further development of lirentelimab and reduced its workforce.
Financial Performance4Q23 Operating Expenses of $65M were above consensus estimates, driven by higher-than-anticipated R&D costs.
---
Ownership Overview
69.78% Insiders
16.91% Mutual Funds
11.14% Other Institutional Investors
2.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLK FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was $1.00 and its highest was $5.64 in the past 12 months.
What is Allakos Inc’s market cap?
Currently, no data Available
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is May 07, 2024 which is in 12 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Mar 14, 2024. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.474 by -$0.236.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -$0.44.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 87,873,990 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.474. Following the earnings report the stock price went up 0.769%.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Blackstone Inc.. It holds Allakos Inc’s shares valued at 11M.
---
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (300.00% Upside)
$4.00 (300.00% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 122.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.9%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.72%
12-Months-Change
Fundamentals
Return on Equity
-77.50%
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
ALLK Stock 12 Months Forecast
Average Price Target
$4.00
▲(300.00% Upside)
Technical Analysis
Best Analysts Covering ALLK
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+49.86%
upgraded a buy rating 4 months ago
Copying Tim Lugo's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +49.86% per trade.
---